Ping An Biomedical Co., Ltd. filed a Form 6-K with the SEC on November 5, 2026, disclosing that on November 4, 2026, it entered into a patent transfer and purchase agreement to acquire three tumor cell-related medical technology patents for an aggregate consideration of USD 2.3 million.

Key Highlights

  • Agreement date: The patent transfer and purchase agreement was entered into on November 4, 2026.
  • Seller: The counterparty is Future Biotechnology Group Co., Limited, according to the filing.
  • Assets acquired: Three tumor cell-related medical technology patents are the subject of the Purchase Agreement.
  • Purchase price: The aggregate consideration is USD 2.3 million, as disclosed in the filing.
  • Closing conditions: The filing states that closing "is subject to the satisfaction of all of the closing conditions set forth in the Purchase Agreement."
  • Signatory: The report was signed by Pijun Liu, Chairperson of the Board of Directors, on November 5, 2026.

Ping An Biomedical's Patent Acquisition from Future Biotechnology Group

According to the Form 6-K filed with the U.S. Securities and Exchange Commission, Ping An Biomedical Co., Ltd. (NASDAQ:PASW) entered into a patent transfer and purchase agreement on November 4, 2026, with Future Biotechnology Group Co., Limited. The company disclosed that the agreement covers the acquisition of three tumor cell-related medical technology patents for an aggregate consideration of USD 2.3 million.

The filing notes that the closing of the transaction remains contingent on the satisfaction of all closing conditions set forth in the Purchase Agreement. No further details regarding those conditions are provided in the body of the 6-K. The company also issued a press release on November 4, 2026, which is filed as Exhibit 99.1 to the report and incorporated by reference.

Ping An Biomedical Co., Ltd. is a foreign private issuer headquartered at 22/F, China United Plaza, 1002-1008, Tai Nan West Street, Cheung Sha Wan, Kowloon, Hong Kong. The company files annual reports under Form 20-F, as indicated on the cover page of the filing. The report was submitted for the month of November 2026 under Commission File Number 001-42155.

What Was Disclosed

Ping An Biomedical Co., Ltd. disclosed a patent purchase agreement signed on November 4, 2026, to acquire three tumor cell-related medical technology patents from Future Biotechnology Group Co., Limited for USD 2.3 million, subject to closing conditions.